AveXis gene therapy awarded SAKIGAKE designation for SMA Type 1 – Seeking Alpha
|
AveXis gene therapy awarded SAKIGAKE designation for SMA Type 1
Seeking Alpha Japan's Ministry of Health, Labour and Welfare has granted SAKIGAKE Designation for AveXis' (NASDAQ:AVXS) AVXS-101, for the treatment of spinal muscular atrophy (SMA) Type 1. The designation was based on data from the Phase 1 clinical trial of the … |
